Logo - http://photos.prnewswire.com/prnh/20160321/346288LOGO
The IQQA® platform and product suite was developed to optimally use multimodality imaging and coordinate the workflow of multiple stakeholders along the continuum of care, including radiologists, interventional radiologists, surgeons and oncologists. IQQA®-BodyImaging, provides powerful precision 3D imaging analytics features for treatment planning and assessment to support open surgery, interventional procedures, minimally invasive and robotic surgery. IQQA®-Guide supports intra-operative precision 3D navigation. The IQQA® product suite has been cleared by the Food and Drug Administration (FDA). It is the most complete workflow solution for thoracic, abdominal, and pelvic cancer treatment.
Through its proprietary IQQA® Web-enabling technology and clinical partnership, EDDA offers cloud-based OnDemand services that can employ IQQA® applications for treatment planning and assessment—anytime, anywhere, through a real-time interactive interface. Physicians may thus participate from different locations to collaboratively determine optimal surgical plans, and the resulting treatment plan can be immediately employed into procedures inside local operating room.
"EDDA Technology, through its IQQA® Enabling Imaging Platform, provides quantitative, real-time, interactive and personalized precision treatment solutions," said Frost & Sullivan Research Analyst Swathi Allada. "In the rapidly growing field of minimally invasive and robotic surgeries, where multimodality imaging is gaining traction, EDDA's pioneering approach and product offerings are of great significance in ushering in the next generation of treatments."
"Owing to its clinical depth and breadth, EDDA's Product Suite aligns perfectly with the US healthcare system's movement toward more IT workflow-based integration," noted Allada. "EDDA's technology is designed to fit within the existing surgical workflow. An important significance of IQQA® Imaging Platform is that it applies across multiple surgical procedures. With exceptional ease of use and clinical versatility, it facilitates efficiency and precision in treatment planning, guidance, monitoring, and follow-up, thus drastically improving the current standard of care. Its streamlined and real-time interactive processes that reduce the time of planning, treatment and assessment, while increasing overall clinical quality, have earned the IQQA® platform the prestigious 2016 North America Frost & Sullivan Award for Product Leadership."
Each year, Frost & Sullivan presents this award to the company that has developed a product with innovative features and functionality, gaining rapid acceptance in the market. The award recognizes the quality of the solution and the customer value enhancements it enables.
Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.
About EDDA Technology, Inc. (EDDA)
EDDA Technology, Inc. is an innovative clinical solution provider in the rapidly growing field of imaging-guided minimally invasive and robotic treatment. Pioneering a "fully quantitative, real-time interactive" approach to multimodality imaging analysis and guidance, EDDA offers a series of next generation computer-assisted solutions for the entire patient management cycle, by enabling early detection and diagnosis, and enhancing efficiency and precision in treatment planning, guidance, monitoring, and follow-up. EDDA's goal is to deliver, with broad accessibility, advanced imaging analytics technology and services that improve clinical workflow and accuracy. EDDA is headquartered in Princeton, New Jersey, and has subsidiaries in Shanghai and Suzhou, China. IQQA® is a registered trademark of EDDA Technology. www.eddatech.com
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
- The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
- The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Contact Us: Start the discussion
Join Us: Join our community
Subscribe: Newsletter on "the next big thing"
Register: Gain access to visionary innovation
P: 210. 247.3870
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/frost--sullivan-applauds-eddas-iqqa-platform-an-advanced-imaging-analytics-technology-that-improves-clinical-workflow-and-accuracy-300238905.html
SOURCE Frost & Sullivan